Zacks Investment Research upgraded shares of Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) from a sell rating to a hold rating in a research note published on Friday morning.

According to Zacks, “Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products to treat serious illnesses, including cardiovascular and autoimmune diseases. The Company’s clinical-stage programs include one Phase 3 ready program, A-002, and two Phase 2 clinical programs, A-623 and A-001. A-002 and A-001 inhibit a novel enzyme target known as secretory phospholipase A2, or sPLA2. Elevated levels of sPLA2 have been implicated in a variety of acute inflammatory conditions, including acute coronary syndrome and acute chest syndrome, as well as chronic diseases such as stable coronary artery disease. A-623 targets elevated levels of B-lymphocyte stimulator, or BLyS (also known as BAFF), which has been associated with a variety of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), rheumatoid arthritis, multiple sclerosis, Sj√∂gren’s Syndrome, Graves’ Disease and others. Anthera Pharmaceuticals, Inc. is headquartered in Hayward, California. “

ANTH has been the topic of a number of other research reports. Jefferies Group LLC restated a hold rating and set a $2.25 target price on shares of Anthera Pharmaceuticals in a research note on Monday, May 15th. ValuEngine cut shares of Anthera Pharmaceuticals from a sell rating to a strong sell rating in a research note on Friday, June 2nd. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and two have given a buy rating to the company’s stock. Anthera Pharmaceuticals has a consensus rating of Hold and a consensus target price of $10.11.

Shares of Anthera Pharmaceuticals (ANTH) opened at 1.29 on Friday. Anthera Pharmaceuticals has a 12 month low of $1.20 and a 12 month high of $27.36. The firm’s market capitalization is $14.07 million. The company’s 50 day moving average price is $1.41 and its 200-day moving average price is $1.19.

Anthera Pharmaceuticals (NASDAQ:ANTH) last released its earnings results on Wednesday, August 9th. The biopharmaceutical company reported $0.03 EPS for the quarter, topping analysts’ consensus estimates of ($1.09) by $1.12. On average, equities analysts predict that Anthera Pharmaceuticals will post ($3.68) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This article was originally published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this article on another website, it was stolen and republished in violation of international copyright laws. The correct version of this article can be accessed at https://theolympiareport.com/2017/08/28/anthera-pharmaceuticals-inc-anth-raised-to-hold-at-zacks-investment-research.html.

Several large investors have recently added to or reduced their stakes in the stock. UBS Group AG boosted its stake in Anthera Pharmaceuticals by 9.9% in the first quarter. UBS Group AG now owns 375,989 shares of the biopharmaceutical company’s stock valued at $160,000 after buying an additional 33,901 shares during the last quarter. Sabby Management LLC boosted its stake in Anthera Pharmaceuticals by 1,809.7% in the first quarter. Sabby Management LLC now owns 1,757,697 shares of the biopharmaceutical company’s stock valued at $748,000 after buying an additional 1,665,655 shares during the last quarter. Finally, Goldman Sachs Group Inc. boosted its stake in Anthera Pharmaceuticals by 1,376.1% in the first quarter. Goldman Sachs Group Inc. now owns 359,982 shares of the biopharmaceutical company’s stock valued at $153,000 after buying an additional 335,595 shares during the last quarter. Hedge funds and other institutional investors own 27.26% of the company’s stock.

About Anthera Pharmaceuticals

Anthera Pharmaceuticals, Inc (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod.

Get a free copy of the Zacks research report on Anthera Pharmaceuticals (ANTH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Anthera Pharmaceuticals (NASDAQ:ANTH)

Receive News & Ratings for Anthera Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anthera Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.